

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

SET-2

RRID:CVCL_2187

Type: Cell Line

Proper Citation

RRID:CVCL_2187

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2187

Proper Citation: RRID:CVCL_2187

Description: Cell line SET-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Adult acute megakaryoblastic leukemia

Defining Citation: [PMID:10637490](#), [PMID:16408098](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31739141](#)

Comments: Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SET-2

Synonyms: Set-2, Set2, SET2

Cross References: BTO:BTO_0004766, EFO:EFO_0006486, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:804, BioSample:SAMN03473274, BioSample:SAMN10988088, cancercellines:CVCL_2187, Cell_Model_Passport:SIDM00397, ChEMBL-Cells:ChEMBL4523535, ChEMBL-Targets:ChEMBL4523566, Cosmic:1012054, Cosmic:1519162, Cosmic:1633513, Cosmic:1943610, Cosmic:2306995, Cosmic-CLP:1659820, DepMap:ACH-000195,

DSMZ:ACC-608, DSMZCellDive:ACC-608, EGA:EGAS00001000610, EGA:EGAS00001002554, GDSC:1659820, GEO:GSM887564, GEO:GSM888647, GEO:GSM1374868, GEO:GSM1446764, IARC_TP53:28307, LiGeA:CCL_845, Lanza:1318, PharmacDB:Set2_1364_2019, Progenetix:CVCL_2187, PubChem_Cell_line:CVCL_2187, Wikidata:Q54952857

ID: CVCL_2187

Record Creation Time: 20220427T221537+0000

Record Last Update: 20260904T015644+0000

Ratings and Alerts

No rating or validation information has been found for SET-2.

No alerts have been found for SET-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. Cell, 189(1), 215.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Wen J, et al. (2026) Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms. Cancer cell.

Le BV, et al. (2026) Pol? activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. Cell reports. Medicine, 7(3), 102687.

Fiskus W, et al. (2025) Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood advances, 9(21), 5598.

Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood, 145(6), 612.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. Cancer research communications, 5(11), 2012.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. *Cancer discovery*.

Cai W, et al. (2024) Augmenting CAR T-cell Functions with LIGHT. *Cancer immunology research*, 12(10), 1361.

Kansy AG, et al. (2024) Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells. *Molecular oncology*, 18(8), 1958.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. *Cell reports. Medicine*, 5(6), 101592.

Ben-Crentsil NA, et al. (2024) RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. *Cancer discovery*, 14(12), 2509.

Pritchard JE, et al. (2024) Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. *Cell reports*, 43(1), 113608.

Arwood ML, et al. (2023) New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. *Cell chemical biology*, 30(6), 618.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 943.

Saleiro D, et al. (2023) Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. *Cancer research communications*, 3(5), 943.

Radzisheuskaya A, et al. (2023) An alternative NURF complex sustains acute myeloid leukemia by regulating the accessibility of insulator regions. *The EMBO journal*, 42(24), e114221.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. *Cancer cell*, 40(3), 301.

Hernández-Malmierca P, et al. (2022) Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell stem cell*, 29(5), 760.